Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review
Tóm tắt
Từ khóa
Tài liệu tham khảo
Aversa F, Tabilio A, Velardi A, et al (1998) Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 339:1186
Barnes DWH, Corp MJ, Loutit JF, et al (1956) Treatment of murine leukaemia with x-rays and homologous bone marrow. Br Med J 2:626
Baron F, Beguin Y (2002) Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 8:351
Baron F, Turhan AG, Giron-Michel J, et al (2002) Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood 99:2107
Bensinger WI, Martin PJ, Storer B, et al (2001) Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344:175
Blaise D, Kuentz M, Fortanier C, et al (2000) Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. J Clin Oncol 18:537
Chakraverty R, Peggs K, Chopra R, et al (2002) Limiting transplantation-related mortality following unrelated donor stem cell transplantion by using a nonmyeloablative conditioning regimen. Blood 99:1071
Champlin R, Giralt S, Gajewski J, et al (1995) CD8 depleted donor lymphocytes for CML relapsing post BMT. Int Soc Exp Hematol 23:939
Childs R, Chernoff A, Contentin N, et al (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750
Childs R, Clave E, Contentin N, et al (1999) Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94:3234
Clift RA, Radich J, Appelbaum FR, et al (1999) Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogeneic marrow transplants during chronic phase of chronic myeloid leukemia. Blood 94:3960
Collins RH Jr, Shpilberg O, Drobyski WR, et al (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433
Couban S, Simpson DR, Barnett MJ, et al (2002) A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100:1525
Dazzi F, Szydlo RM, Craddock C, et al (2000) Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 95:67
Drobyski WR, Hessner MJ, Klein JP, et al (1999) T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation [erratum appears in Blood 2000 95:1137]. Blood 94:434
Epstein RB, Storb R, Ragde H, et al (1968) Cytotoxic typing antisera for marrow grafting in littermate dogs. Transplantation 6:45
Feinstein LC, Sandmaier BM, Hegenbart U, et al (2003) Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br J Haematol 120:281
Flowers MED, Traina F, Storer B, et al (2003) Risk factors for severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation for treatment of hematological malignancies. Blood 102:524
Fukuda T, Boeckh M, Carter RA, et al (2003) Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 102:827
Fukuda T, Hackman RC, Guthrie KA, et al (2003) Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 102:2777
Gale RP, Horowitz MM, Ash RC, et al (1994) Identical twin bone marrow transplants for leukemia. Ann Intern Med 120:646
Giralt S, Estey E, Albitar M, et al (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531
Giralt S, Thall PF, Khouri I, et al (2001) Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97:631
Gluckman E, Rocha V, Boyer-Chammard A, et al (1997) Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 337:373
Goldman JM, Apperley JF, Jones L, et al (1986) Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 314:202
Hogan WJ, Maris M, Storer B, et al (2004) Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 103:78
Hurley C, Baxter Lowe LA, Logan B, et al (2003) National marrow donor program HLA matching guidelines for unrelated marrow transplants. Biol Blood Marrow Transplantat 9:610
Hurley CK, Fernandez VM, Setterholm M (2003) Maximizing optimal hematopoietic stem cell donor selection from registries of unrelated adult volunteers. Tissue Antigens 61:415
Junghanss C, Marr KA, Carter RA, et al (2002) Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 8:512
Junghanss C, Storb R, Boeckh M (2002) Risk of cytomegalovirus infection after transplantation with nonmyeloablative and reduced-intensity conditioning regimens. Blood 100:2675
Khouri IF, Keating M, Körbling M, et al (1998) Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16:2817
Khouri IF, Saliba RM, Giralt SA, et al (2001) Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98:3595
Kolb HJ, Mittermüller J, Clemm CH, et al (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462
Kolb HJ, Schattenberg A, Goldman JM, et al (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041
Kolb HJ, Schmidt C, Barrett AJ, et al (2004) Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103:767
Kottaridis PD, Milligan DW, Chopra R, et al (2000) In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96:2419
Lee SJ, Vogelsang G, Flowers MED (2003) Chronic graft-versus-host disease. Biol Blood Marrow Transplantat 9:215
Little M-T, Baker JE, Sandmaier BM, et al (2002) Kinetics of mixed chimerism in peripheral blood hematopoietic subpopulations from 120 patients after nonmyeloablative hematopoietic stem cell transplant. Blood 100:136
Little M-T, Storb R (2002) History of haematopoietic stem-cell transplantation. Nat Rev Cancer 2:231
Lorenz E, Uphoff D, Reid TR, et al (1951) Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 12:197
Maloney DG, Molina AJ, Sahebi F, et al (2003) Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102:3447
Maris M, Boeckh M, Storer B, et al (2003) Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp Hematol 31:941
Maris MB, Niederwieser D, Sandmaier BM, et al (2003) HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 102:2021
Marmont AM, Horowitz MM, Gale RP, et al (1991) T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120
McSweeney PA, Niederwieser D, Shizuru JA, et al (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390
Mielcarek M, Martin PJ, Leisenring W, et al (2003) Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102:756
Molina AJ, Storb RF (2000) Hematopoietic stem cell transplantation in older adults. In: Rowe LM, Lazarus HM, Carella AM (eds) Handbook of bone marrow transplantation. Martin Dunitz, London, pp 111–137
Nash RA, Antin JH, Karanes C, et al (2000) Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96:2062
Niederwieser D, Maris M, Shizuru JA, et al (2003) Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101:1620
Or R, Shapira MY, Resnick I, et al (2003) Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101:441
Perez-Simon JA, Kottaridis PD, Martino R, et al (2002) Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100:3121
Powles R, Mehta J, Kulkarni S, et al (2000) Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 355:1231
Przepiorka D, Weisdorf D, Martin P, et al (1995) 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825
Randolph SSB, Gooley TA, Warren EH, et al (2004) Female donors contribute to a selective graft versus leukemia effect in male recipients of HLA matched related hematopoietic cell transplants. Blood 103:347
Ratanatharathorn V, Nash RA, Przepiorka D, et al (1998) Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host-disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92:2303
Sandmaier BM, Maris M, Maloney DG, et al (2003) Low-dose total body irradiation (TBI) conditioning for hematopoietic cell transplants (HCT) from HLA-matched related (MRD) and unrelated (URD) donors for patients with hematologic malignancies: a five-year experience. Blood 102:264
Santos GW, Sensenbrenner LL, Burke PJ, et al (1971) Marrow transplantation in man following cyclophosphamide. Transplant Proc 3:400
Santos GW, Tutschka PJ, Brookmeyer R, et al (1983) Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309:1347
Schmitz N, Bacigalupo A, Hasenclever D, et al (1998) Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21:995
Slattery JT, Clift RA, Buckner CD, et al (1997) Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89:3055
Slavin S, Nagler A, Naparstek E, et al (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756
Slavin S, Naparstek E, Nagler A, et al (1995) Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 23:1553
Socié G, Clift RA, Blaise D, et al (2001) Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of the 4 randomized studies. Blood 98:3569
Sorror ML, Maris M, Storer B, Sandmaier BM, Diaconescu R, Flowers C, Maloney DG, Storb R (2004) Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities. Blood DOI 10.1182/blood-2004-02-0545
Sorror ML, Maris M, Storer B, et al (2003) Nonmyeloablative (NM) conditioning and allogeneic hematopoietic cell transplantation (HCT) with HLA-matched unrelated donor (URD) for patients (Pts) with chemotherapy-refractory chronic lymphocytic leukemia (CLL). Blood 102:1757
Spitzer TR, McAfee S, Sackstein R, et al (2000) Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 6:309
Storb R, Bryant JI, Buckner CD, et al (1973) Allogeneic marrow grafting for acute lymphoblastic leukemia: Leukemic relapse. Transplant Proc 5:923
Storb R, Deeg HJ, Farewell V, et al (1986) Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 68:119
Storb R, Deeg HJ, Whitehead J, et al (1986) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729
Storb R, Epstein RB, Bryant J, et al (1968) Marrow grafts by combined marrow and leukocyte infusions in unrelated dogs selected by histocompatibility typing. Transplantation 6:587
Storb R, Epstein RB, Graham TC, et al (1970) Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 9:240
Storb R, Raff RF, Appelbaum FR, et al (1988) What radiation dose for DLA-identical canine marrow grafts? Blood 72:1300
Storb R, Yu C, Wagner JL, et al (1997) Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89:3048
Storb RF, Lucarelli G, McSweeney PA, et al (2003) Hematopoietic cell transplantation for benign hematological disorders and solid tumors. Hematology (Am Soc Hematol Educ Program) :372
Thomas ED, Buckner CD, Banaji M, et al (1977) One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 49:511
Thomas ED, Buckner CD, Clift RA, et al (1979) Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 301:597
Thomas ED, Clift RA, Fefer A, et al (1986) Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104:155
Thomas ED, Lochte HL Jr, Lu WC, et al (1957) Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 257:491
Thomas ED, Sanders JE, Flournoy N, et al (1979) Marrow transplantation for patients with acute lymphoblastic leukemia in remission. Blood 54:468
Van Bekkum DW, Vries MJ de (1967) Radiation chimaeras. Academic Press, New York
Wagner JE, Barker JN, Defor TE, et al (2002) Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100:1611
Weiden PL, Flournoy N, Thomas ED, et al (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300:1068
Weiden PL, Sullivan KM, Flournoy N, et al (1981) Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304:1529
Weissinger F, Sandmaier BM, Maloney DG, et al (2001) Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 98:3584
Yu C, Seidel K, Nash RA, et al (1998) Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 91:2581